Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
James L. Gulley(National Cancer Institute), William L. Dahut(National Cancer Institute), Francis Sullivan, Jennifer L. Marté(National Cancer Institute), Patricia K. Beetham(National Institutes of Health), Kevin Camphausen(National Cancer Institute), Seth M. Steinberg(National Institutes of Health), C. Norman Coleman(Unknown), Jeffrey Schlom(National Cancer Institute), Anne Bastian(National Institutes of Health), Philip M. Arlen(Dana-Farber Cancer Institute), Steven Morin(National Institutes of Health), Kwong‐Yok Tsang(National Institutes of Health), James W. Hodge(National Cancer Institute), Cynthia Ménard(National Institutes of Health), Junko Yokokawa(National Institutes of Health)
Cited by 371
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|973
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817